Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 19, Issue 33, Pages 5485-5492Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v19.i33.5485
Keywords
Pancreatic cancer; Propofol; Gemcitabine; Nuclear factor-kappa B; Apoptosis
Categories
Ask authors/readers for more resources
AIM: To investigate the effect of propofol on human pancreatic cells and the molecular mechanism of propofol action. METHODS: We used the human pancreatic cancer cell line MIAPaCa-2 for in vitro studies measuring growth inhibition and degree of apoptotic cell death induced by propofol alone, gemcitabine alone, or propofol followed by gemcitabine. All experiments were conducted in triplicate and carried out on three or more separate occasions. Data were means of the three or more independent experiments +/- SE. Statistically significant differences were determined by two-tailed unpaired Student's t test and defined as P < 0.05. RESULTS: Pretreatment of cells with propofol for 24 h followed by gemcitabine resulted in 24%-75% growth inhibition compared with 6%-18% when gemcitabine was used alone. Overall growth inhibition was directly correlated with apoptotic cell death. We also showed that propofol potentiated gemcitabine-induced killing by downregulation of nuclear factor-kappa B (NF-kappa B). In contrast, NF-kappa B was upregulated when pancreatic cancer cells were exposed to gemcitabine alone, suggesting a potential mechanism of acquired chemoresistance. CONCLUSION: Inactivation of the NF-kappa B signaling pathway by propofol might abrogate gemcitabine-induced activation of NF-kappa B, resulting in chemosensitization of pancreatic tumors to gemcitabine. (C) 2013 Baishideng. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available